peoplePerson
Clemens Kratochwil
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Clemens Kratochwil published the first clinical experience with 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer, launching the alpha-emitter era in prostate cancer.
Role
Nuclear medicine physician, Heidelberg University Hospital
Institution
Specialisms
Targeted alpha therapyPSMA radioligandsDosimetry
Profiles
| Title | Journal | Year |
|---|---|---|
| 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer | Journal of Nuclear Medicine | 2016 |
Pages like this
not linked directly; found by shared links- TrialAlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
- CompanyFusion Pharmaceuticals (AstraZeneca)
- IdeaAlpha-emitting PSMA therapy at first metastatic diagnosis
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
- PersonUwe Haberkorn
Shares European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, PSMA.
- PersonFrederik Giesel
Shares European Association of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ.
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
- CompanyClarity Pharmaceuticals
Shares PSMA, Prostate cancer.